All News

pill,ASA,colchcine,small

Colchicine Ineffective in Long COVID

Jack Cush, MD

Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory markers. 

Read Article
autoimmune.disease

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease

Jack Cush, MD

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.

Read Article
FDA%20approved2.jpg

FDA Approves Obinutuzumab for Active Lupus Nephritis

Jack Cush, MD

The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.

Read Article
RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
lupus_0.jpg

Telitacicept Effective in Systemic Lupus Erythematosus

Jack Cush, MD

The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.

Read Article
DXA1.jpg (keep)

Why Brittle Bones Aren't Just a Woman's Problem

MedPage Today

Ronald Klein was biking around his neighborhood in North Wales, Pennsylvania, in 2006 and tried to jump a curb. "But I was going too slow -- I didn't have enough momentum," he recalled. As the bike toppled, he thrust out his left arm to break the fall. It didn't seem like a serious accident, yet "I couldn't get up," he said.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy Management in Inflammatory Bowel Disease: A Global Consensus

Jack Cush, MD

Consensus guidance on the management of pregnancy in patients with inflammatory bowel disease (IBD) was simultaneously published in six international journals, including The American Journal of Gastroenterology.

Read Article
30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD was found in 36%. MTX & biologics were not linked to NAFLD or fibrosis -- BUT was signif assoc w/ metabolic syndr, BMI, Waist, ALT, and AST (all p < .001) https://t.co/MpkxjHEbxK
Dr. John Cush RheumNow ( View Tweet)
Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/lwq8ZUMTQ8
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of biopsy proven lupus nephritis pts (1970-2024) - a total of 324 LN pts followed for median 9.9 yrs -- 30 (9.3%) developed Venous Thromboembolic event (VTE); time from LN to 1st VTE 4.4 yrs. Predictors were SLEDAI-2K score (HR= 1.05) and proteinuria level (HR 1.26)

Dr. John Cush RheumNow ( View Tweet)

From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials https://t.co/zZAwYINmC2
Dr. John Cush RheumNow ( View Tweet)
Failure of IL-17 inhibition in Lupus nephritis. 31 LN pts enrolled in phase 2 DBRPCT of secukinumab 300 mg IV, but was terminated early for futility (complete renal response at week 52 was lower with secukinumab (24.2%) than with placebo (36.3%). https://t.co/471TolqtFk https://t.co/gKi2Z2MZHS

Links:

Dr. John Cush RheumNow ( View Tweet)
Muscle mass & JAKi? 15 active RA pts (+ sarcopenia risk) Rx w/ tofacitinib - signif. improved @1 mo. @6 mos muscle mass signif improved (+242 cm3, +4%, p=0·017) {less w/ NSAIDs); w/ signif creatinine incr (0.06 mg/dl) & decr in serum IL-6, IL-1 & TNF. No change in CK, myoglobin, https://t.co/taY7DisMOS
Dr. John Cush RheumNow ( View Tweet)
A cohort study of 1 548 538 mother-child pairs with antenatal exposure to steroids (ACS) found a significantly increased risk of res v nonrespiratory infections in preterm & full-term children up to 21 years. (incidence rate, 65 vs 40 & 30 vs 18 per 1000 person-Yrs, https://t.co/Vh4TNYMXgo
Dr. John Cush RheumNow ( View Tweet)
Tertiary center study of 147 GPA pts (age ~45, 18 mos F/U) - total of 55 deaths& 179 relapses (in 117 pts;1.53/pt). Predictors of relapse (~2 fold incr) = Age > 55, male, ^^creatinine & CNS dz. Mortality assoc w/ ≥ 55 yrs, male, creatinine >1.3, CNS @baseline https://t.co/GzScokrN7G
Dr. John Cush RheumNow ( View Tweet)
Eating Crow (10.10.2025) Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow. https://t.co/n5W8c7OeKS https://t.co/LXAxrE37WS

Links:

Dr. John Cush RheumNow ( View Tweet)
Tramadol not effective at chronic pain The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine. https://t.co/zFWwyy1j3O
Dr. John Cush RheumNow ( View Tweet)
FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. https://t.co/pIQwyLUBoj
Dr. John Cush RheumNow ( View Tweet)
Taiwan study of HBV or HCV reactivation w/ bDMARD use in PsO & PsA - among 5527 treatment episodes (3197 ts/bDMARDs) found a 10% risk of reactivation of HBVr (10.6%) & HCV (9.9%), highest w/ TNFi. Reactivation assoc w/ TNFi, HBsAg+, HBeAg+, immunosuppressant use without antiviral https://t.co/AwpmRpfJUT
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×